High-Grade Vulvar, Vaginal, and Anal Precancers Among U.S. Adolescents and Young Adults After Human Papillomavirus Vaccine Introduction.

This study included data from the Surveillance, Epidemiology, and End Results (SEER) Program during 2000–2017 from 18 central cancer registries covering 27.8% of the U.S. population. Most cancer registries stopped routinely collecting high-grade cervical precancer data in 1996, but SEER registries continued to require reporting of high-grade vulvar intraepithelial neoplasia grade 3 (VIN3), vaginal intraepithelial neoplasia Grade 3 (VAIN3), and anal intraepithelial neoplasia Grade 3 (AIN3). 13 Noninvasive cases were identified using the International Classification of Diseases for Oncology, Third Edition site Codes C51 (VIN3), C52 (VAIN3), and C21 and C20.9 (AIN3), and histology codes were limited to squamous cell histology (8050–8084 and 8120–8131). Incidence rates per 100,000 population were calculated using SEER*Stat, version 8.3.8, 14 and were stratified by age group (15 –29 and 30–39 years). The larger number of VIN3 cases allowed more detailed age categories (15–19, 20–24, 25–29, 30–34, 35–39 years). The year of diagnosis was grouped into 2-year intervals because of sparse data. Changes in rates during 2000–2017 were evaluated using Joinpoint regression, version 4.8.0.1, 15 which fits a series of joined straight lines on a logarithmic scale to the trends in the annual age-standardized rates. 16 Year of diagnosis was included as a continuous independent variable using the midpoint of each interval. A total of 9 observation points allowed a maximum of 1 Joinpoint (2-line segments). The line segment trend was used to quantify the annual percentage change (APC). The average APC (AAPC) for 2000–2017 was calculated using a weighted average of the slope coefficients of the underlying Joinpoint regression line with the weights equal to the length of each segment over the interval. The Bayesian Information Criterion was used for model selection and the empirical quantile method (Method 2) to calculate APC CIs. 17 Rates were considered to increase if the APC was >0 and to decrease if it was <0 ( p <0.05); otherwise, rates were considered stable. All analyses were conducted in 2020.

During 2000–2017, a total of 6,128 VIN3, 945 VAIN3, 462 AIN3 cases among females and 2,154 AIN3 cases among males were identified. Most VIN3 and VAIN3 cases were among females aged 30–39 years (62.8% and 60.7%, respectively) and non-Hispanic White females (64.6% and 61.1%, respectively). Most AIN3 cases were among females and males aged 30–39 years (77.9% and 77.1% respectively), with non-Hispanic White persons comprising the largest group (55.8% female and 46.0% male) ( Table 1 ). Incidence rates of VIN3 increased by 6.1% (2000 –2007), 20.9% (2000–2005), and 4.8% (2000–2009) per year among females aged 15–19, 20–24, and 25–29 years, respectively ( Figure 1 ). VIN3 rates then decreased by 21% (2007–2017), 11.2% (2005–2017), and 7.6% (2009–2017) per year among females aged 15–19, 20–24, and 25–29 years, respectively. Among females aged 30–34 and 35–39 years, VIN3 rates were stable. During 2000–2009, VAIN3 rates were stable among females aged 15–29 years and increased by 4.7% per year among females aged 30–39 years. The rates then decreased by 19.1% per year (2009–2017) and 5.6% per year (2009–2017) among females aged 15–29 and 30–39 years, respectively. The rates of AIN3 increased by 14.8% per year during 2000–2013 and were stable during 2013–2017 among females aged 15–29 years. Among females aged 30–39 years, the rates increased by 6.3% per year during 2000–2017. AIN3 rates increased by 35.0% per year during 2000–2007 and increased by 7.0% per year during 2007–2017 among males aged 15–29 years. Among males aged 30–39 years, the rates increased by 7.1% per year during 2000–2009 and were stable during 2009–2017.

After HPV vaccine introduction, the largest decreases in incidence rates of VIN3 and VAIN3 occurred among the youngest females. These declines are similar to those observed among high-grade cervical precancers after HPV vaccine introduction 6 – 8 and may suggest vaccine impact. In addition, after a prevaccination period when AIN3 rates increased, the rates were stable among females aged 15–29 years and among males aged 30–39 years after HPV vaccine introduction. U.S. HPV vaccine coverage has been increasing since its introduction: in 2019, a total of 69.9% of female adolescents and 66.3% of male adolescents had received at least 1 dose. 18 Decreases in the incidence of HPV infection, 3 anogenital warts, 19 and cervical precancers 7 , 8 have been observed within 4 years of HPV vaccine introduction, attributable to both direct vaccine protection and herd immunity. Among cervical precancers, the largest decreases in the incidence have been found among younger females, who are more likely to have been vaccinated. 6 – 8 Our study findings support that decreasing incidence may also be occurring among the youngest age groups for other HPV-associated precancers, especially vaginal and vulvar precancers. The story is a bit more complicated with AIN3 because the rates stabilized after HPV vaccine introduction among women aged 15–29 years and males aged 30–39 years but without significant declines. In addition, AIN3 rates among younger males continued to increase but at a lower rate than before HPV vaccine introduction. These findings may be due to very few diagnosed cases among younger females, a later recommendation for routine vaccination among males, and cases occurring among males who may have not benefited directly from herd immunity. Although routine screening is not recommended for anogenital cancers other than cervical cancer, these precancers can be diagnosed opportunistically during cervical cancer screening. Changes in screening guidelines and recommendations 20 may have affected the detection of VIN3, VAIN3, and AIN3 among women. Higher AIN3 detection among males compared to females could be a result of increased anal cytologic screening in geographic areas with a high prevalence of HIV infection. 11 Nonsystematic detection of these endpoints adds variation to the time interval between incidence and detection that could affect the reliability of the trends in diagnosis to reflect early HPV vaccine impact. A clinical trial of HPV efficacy against VIN3 and AIN3 is in progress. 21 This study had at least 3 limitations. First, most cancer registries stopped collecting cervical precancer data in 1996 because of concerns about appropriate case definitions, diagnostic terminology changes, and increased diagnosis or treatment in outpatient settings. 22 These changes may have resulted in decreased reporting of VIN3, VAIN3, and AIN3. Second, age groups were based on sparse data that were not optimized for evaluating vaccine impact. Third, factors not routinely collected by SEER, including vaccination status, HPV type, screening, and HIV status, could not be examined. The strength of this study was the use of high-quality population-based cancer registry data designed to be representative of the U.S. general population. Cancer registries outside of the SEER program also collect VIN3, VAIN3, and AIN3 data but are not reportable at the federal level. Continued collection of these data in sentinel sites and expanding reportability could enhance the ability to examine the impact of HPV vaccine as vaccinated cohorts enter screening programs.

Decreasing rates in VIN3 and VAIN3 among younger age groups is analogous to decreases observed in cervical precancers, which have been attributed to the introduction of the HPV vaccine. This is a key step toward building population-level data on the impact of HPV vaccine in noncervical HPV-associated anogenital precancers. In addition, anal precancers stabilized in the years after HPV vaccine introduction, which is a promising finding. Continued collection of precancer data by sentinel cancer registry sites will be important to examining HPV impact among HPV-associated anogenital cancers.

Human papillomavirus (HPV) causes nearly all cervical cancers and a large proportion of vaginal, vulvar, and anal cancers. 1 In contrast to cervical cancer, 2 understanding of carcinogenic progression at noncervical anogenital sites is limited because screening is not routinely performed and detection is opportunistic. Since the introduction of routine HPV vaccination at age 11–12 years (2006 for girls and 2011 for boys) in the U.S., decreases occurred in vaccine-type HPV infections, 3 , 4 anogenital warts, 5 cervical precancers, 6 – 8 and invasive cervical cancers. 9 Population-level impact of HPV vaccine on vulvar, vaginal, and anal precancers is unknown because few registries collect these cases. Published U.S. incidence trends of vulvar and anal precancers 10 – 12 have not yet examined the rates in the years after HPV vaccine implementation or among younger cohorts more likely to be vaccinated. This study used population-based cancer registries and examined recent trends in high-grade vulvar, vaginal, and anal precancers among persons aged 15–39 years in the U.S.